{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-104102","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.724218+00:00","generated_at":"2026-05-15T13:34:42.869663+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bolt Biotherapeutics reports FY2025 loss from ops $36.1M; cash $31.8M into 2027","bullets":["Collaboration revenue $7.7M for FY2025, flat YoY; Q4 2025 revenue $2.5M vs $0 in Q4 2024.","R&D expenses $28.5M in FY2025, down from $57.5M in FY2024; G&A $13.8M vs $18.5M, driven by restructuring.","Loss from operations $36.1M for FY2025 vs $73.0M in FY2024.","Cash, cash equivalents and marketable securities $31.8M as of Dec 31, 2025; expected to fund milestones into 2027.","Initial clinical data for BDC-4182 Phase 1 study (CLDN18.2) expected in Q3 2026; step-up dosing added to protocol."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-104102","json":"https://secwatch.observer/filing/0001193125-26-104102.json","markdown":"https://secwatch.observer/filing/0001193125-26-104102.md","text":"https://secwatch.observer/filing/0001193125-26-104102.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/0001193125-26-104102-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/bolt-20260312.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T13:34:42.869663+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a7815297eeaf5e99c93b767bea96782a4e8988bc","claim":"Bolt Biotherapeutics, Inc. reported the fourth quarter ended December 31, 2025 results: revenue $2.5 million.","evidence_excerpt":"Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/0001193125-26-104102-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2025"},{"label":"Revenue","value":"$2.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d0822eed7c835d06ab2842072792e5e1525c19d9","claim":"Bolt Biotherapeutics, Inc. reported the full year ended December 31, 2025 results: revenue $7.7 million.","evidence_excerpt":"Total collaboration revenue was $2.5 million and $7.7 million for the fourth quarter and full year ended December 31, 2025, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/0001193125-26-104102-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Revenue","value":"$7.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}